BPC-157 is a synthetic chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). The sequence comes from a larger protein called Body Protection Compound that was identified in human gastric juice. Pavle Sikiric and colleagues first described the fragment in 1993, and most of the published work since then carries their group's name. You will also see it listed as PL-10, PLD-116, PL 14736, or by its CAS number 137525-51-0.
The "gastric" origin matters because the earliest experiments were about the gut: protecting stomach mucosa, healing ulcers, and reducing intestinal inflammation in rodents. The peptide later got studied across a much wider range of injury models.
Proposed mechanisms
These come almost entirely from animal and cell studies, so treat them as proposed rather than settled.
- Nitric oxide system. A 2025 review in Pharmaceuticals calls the NO system the peptide's main molecular target, with interaction at endothelial nitric oxide synthase (eNOS). (review)
- Angiogenesis. Studies report upregulation of VEGFR2, the receptor tied to new blood-vessel formation, which is the usual explanation offered for the wound-healing findings.
- Antioxidant and growth-factor signaling. Reported effects on free-radical scavenging and on growth-factor pathways round out the picture.
What the evidence actually covers
Here is the honest part. The preclinical literature is large. The human literature is almost empty.
In rats and mice, BPC-157 has been studied in gastric ulcer, NSAID-induced injury, inflammatory bowel models, fistulas, and tendon, muscle, and nerve injury. Those are real published experiments, but they are animal experiments. Rodent physiology is not human physiology, and effects in one do not guarantee effects in the other.
The Croatian company Pliva developed the peptide as PL 14736 for ulcerative colitis and ran early clinical work. A Phase I safety study in healthy volunteers was registered around 2015 and then cancelled in 2016. No large, peer-reviewed, controlled human efficacy trial has been published. The 2025 review puts it bluntly: human studies are scarce. Anti-doping authorities make the same point from the safety side. USADA notes that because BPC-157 has not been studied much in people, no one knows what a safe dose would be.
Regulatory and sport status
BPC-157 is not an approved drug in the US, EU, or elsewhere. The NCATS Inxight: Drugs entry lists it without any marketing approval.
In sport, WADA added BPC-157 to its Prohibited List under category S0 (non-approved substances), prohibited at all times, with no Therapeutic Use Exemptions available. For athletes that is a clear line: using it risks a sanction.
Its US compounding status has moved around. The FDA placed BPC-157 in the Category 2 bucket (not eligible for pharmacy compounding under sections 503A/503B), a status that has since shifted as nominations changed. Because rules here are live and can change, confirm the current FDA position before relying on any compounding claim.
Nothing here is medical or dosing advice. Material sold for laboratory use is research-use-only and not for human consumption.
The quality angle for buyers
Because BPC-157 isn't an approved pharmaceutical, anything on the market is unregulated. Regulators have flagged it turning up in wellness products it has no business being in. That puts the whole burden of trust on the seller. The questions that matter are basic and verifiable: is there a recent third-party certificate of analysis confirming identity (that the vial actually contains this 15-mer) and purity (typically by HPLC and mass spec), and does the lot number on the COA match the vial? peptideone aggregates independent vendor and testing signals so those claims can be checked side by side rather than taken on faith.